News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 03/10/2026 HKT			5-day change	1st Jan Change
10.50 ^USD	-6.75%		-10.79%	-33.04%

10-01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
10-01	Monte Rosa Therapeutics, Inc. - Special Call

All News

Mentions Relevance

10-03	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
10-01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI
10-01	Monte Rosa Therapeutics, Inc. - Special Call
10-01	Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study	MT
10-01	Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk	GL
10-01	HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target	MT
10-01	Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk	GL
09-08	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI
09-08	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
09-03	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
09-01	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI
08-24	Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	GL
08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT
08-06	Monte Rosa Therapeutics: Q2 Earnings Snapshot	AQ
08-06	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	GL
07-31	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
07-03	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
06-30	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
06-30	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI